Cosmos Health (NASDAQ:COSM – Get Free Report) and Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
Volatility and Risk
Cosmos Health has a beta of 4.83, suggesting that its share price is 383% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
Profitability
This table compares Cosmos Health and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cosmos Health | -30.41% | -52.85% | -17.87% |
| Enanta Pharmaceuticals | -89.56% | -64.04% | -20.22% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cosmos Health | $65.27 million | 0.31 | -$19.15 million | ($0.64) | -0.51 |
| Enanta Pharmaceuticals | $65.32 million | 6.18 | -$81.89 million | ($2.59) | -5.36 |
Cosmos Health has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Cosmos Health and Enanta Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cosmos Health | 1 | 0 | 0 | 0 | 1.00 |
| Enanta Pharmaceuticals | 1 | 0 | 7 | 0 | 2.75 |
Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 46.06%. Given Enanta Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Cosmos Health.
Insider & Institutional Ownership
12.6% of Cosmos Health shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 26.2% of Cosmos Health shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Cosmos Health beats Enanta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Cosmos Health
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
